Promega, J3355, Membrane VEGF Target Cells

Assess the Mechanism of Action of Biologics Designed to Affect VEGF Signaling
Prequalified according to ICH guidelines
96- and 384-well plate formats
No primary cell culture required
Supplied in convenient thaw-and-use format; also available in cell propagation model (CPM) format
Specifications：
Membrane VEGF Target Cells J335A 1 × 0.5ml
Membrane VEGF Target Cells J335A 5 × 0.5ml
Membrane VEGF Target Cells (CPM) J334A 2 × 1ml
Vascular endothelial growth factor (VEGF) is an important signaling protein that is secreted from epithelial cells, tumor cells and macrophages. It has many functions, including stimulating angiogenesis, increasing vascular permeability, enhancing tumor invasion and survival, and inhibiting antitumor response in regulatory T cells. Because some VEGF isoforms are membrane-bound (mVEGF), the Fc effector function of VEGF-targeted antibodies needs to be characterized, particularly its potential to induce antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). However, such studies are hampered by the lack of model cell lines naturally expressing mVEGF.
mVEGF Target Cells are a genetically engineered cell line stably expressing a cleavage-resistant form of VEGF that enforces its surface expression. They are designed to be used as target cells in assays that measure the effector functions, such as ADCC and CDC, of anti-VEGF blockers. In addition, they can be used to measure antibody binding affinity to mVEGF.